For the sake of clarity and accuracy, following are some things about #pharmacycompounding reporters should know when reporting on compounding, particularly related to semaglutide:
Download the Traditional Pharmacy Compounding 101 DocumentThe Alliance for Pharmacy Compounding is the voice for pharmacy compounding, representing more than 600 compounding small businesses – including compounding pharmacists and technicians in both 503A and 503B settings – as well as prescribers, educators, researchers, and suppliers. In traditional compounding, pharmacists create a customized medication, most often from pure ingredients, for an individual patient pursuant to a prescription. Pharmacists’ ability to compound medications from pure ingredients is authorized in federal law and for good reason: Manufactured drugs don’t come in strengths and dosage forms that are right for everyone, and prescribers need to be able to prescribe customized medications when, in their judgment, a manufactured drug is not the best course of therapy for a human or animal patient. Every day, APC members play a critical role in patients’ lives, preparing essential, custom medications for a range of health conditions, including autism, oncology, dermatology, ophthalmology, pediatrics, women’s health, animal health, and others.
FDA database showing registered manufacturers of specific APIs/unfinished drug products
To search for FDA-registered manufacturers of a particular API, select the Unfinished Drug Product radio button, select Non Proprietary Name from the drop-down options, and type in the name of the active pharmaceutical ingredient (e.g., semaglutide) you are searching for.
FDA Adverse Events Reporting System (FAERS) Public Dashboard
This database provides details on adverse events reported for FDA-approved drugs. You can search by proprietary or non-proprietary name.